Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Court Shoots Down Norwich In ‘Unprecedented’ Xifaxan ‘Skinny Label’ Claim

Delaware Court ‘Hesitant To Be The First’ To Allow Relief Claim To Proceed

Executive Summary

Coming down heavily on Norwich Pharmaceuticals, a US district court has denied the US-based generics firm’s bid for relief post-judgment in a case involving the “hotly disputed” issue of skinny label ANDA products.

You may also be interested in...

B+L/Novaliq Hope Miebo Can Stand Out In Crowded Dry Eye Field

The companies got US FDA approval for the drug, which they said is the only approved medicine that targets tear evaporation rather than tear production, though its mechanism is not fully understood.

Sandoz Matches Teva On US Rifaximin Launch Date

Sandoz has joined a fellow major generics player, Teva’s Actavis, in settling itself out of litigation with Bausch Health over Xifaxan 550mg tablets in the US. The two settlement agreements contain key similarities and differences.

Actavis finds a Xifaxan date

Teva’s Actavis will be able to offer a generic alternative to Bausch Health’s Xifaxan (rifaximin) 550mg tablets in the US around two years before the longest-lasting US patent protecting the gastrointestinal drug expires. Under the terms of a patent-litigation settlement that ends proceedings in a Delaware district court, Actavis can market, without royalties, its own approved generic of Xifaxan 550mg from 1 January 2028. Alternatively, from the same date, the generics firm can license restricted supplies of an authorised generic.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts